Tous Actualités
Suivre
Abonner Deutsche Effecten- und Wechsel-Beteiligungsges. AG

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

bm-t and DEWB acquire majority shareholding in Zenteris

Erfurt/Jena (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
merger, acquisition and takeover
bm-t beteiligungsmanagement thüringen gmbh
(bm-t), Erfurt and Deutsche Effecten- und 
Wechsel-Beteiligungsgesellschaft AG (DEWB), Jena took a joint stake 
in Zenteris GmbH (Zenteris) at the end of July 2007. In an initial 
round of financing, DEWB, which is listed on the Prime-Standard at 
the German Stock Exchange, took an indirect stake of approx. 39 
percent in the Jena-based company. bm-t acquired approx. 31 percent 
of the shares. The parties agreed not to disclose details on the 
volume of the transaction.
Zenteris develops highly specialised technology solutions for 
identifying biohazardous materials via the optical analysis of 
samples on a biochip platform. The Approve-B system developed by 
Zenteris provides for easy and fast handling when screening for 
various pathogens such as anthrax and plague in a one-step analysis 
and so can be used for numerous applications in the field of safety 
and security technology. Against the background of a global increase 
in the terrorism risk and the use of biotoxins and germ warfare 
agents, increasing importance is being attached to the Zenteris 
technology which is not dependent upon costly laboratory diagnostics.
"The results from research and development to date as well as the 
expertise and sector-related experience of the company´s management 
in the areas of opto-electronics and biotechnology have impressed 
bm-t," says Dr. Guido Bohnenkamp giving the reason for bm-t´s 
commitment to Zenteris. The huge global market potential of this 
technology was another factor.
For DEWB this investment holding represents a further step in its 
strategy of focused investment. "In future we will be extensively 
gearing our investments towards the areas of optics, optical-related 
technologies and sensor systems. With its optical analysis systems, 
Zenteris fits in excellent with our target portfolio," says Falk 
Nuber, Member of the Management Board of DEWB. He is convinced of the
growth potential provided by Zenteris. "The technology and market 
potential of Zenteris offer us the opportunity to participate to a 
significant extent in the future development of the company with a 
manageable investment," continues Nuber.
Dr. Claudia Gluch, Managing Director of Zenteris GmbH, emphasises: 
"Our technologies are also suitable for giving a scientifically sound
and precise picture of the composition of biological substances to 
users who have no deep and detailed technical knowledge of molecular 
biology. As a result in particular of the increasing safety and 
security requirements in both the public and private sector, the use 
of Zenteris products can provide the crucial advantage in the 
identification and elimination of potential hazard sources. Our 
technology possesses great potential in a global growth market."
About bm-t The Erfurt-based company bm-t beteiligungsmanagement 
thüringen gmbh - a subsidiary of the Thüringer Aufbaubank - is the 
management company for four investment funds in which the Free State 
of Thuringia is the main shareholder: TI - Thüringer 
Innovationsfonds, VCT - Venture Capital Thüringen GmbH & Co. KG, TIB 
- Thüringer Industriebeteiligungs GmbH & Co. KG and PET - Private 
Equity Thüringen GmbH & Co. KG. bm-t currently manages more than 40 
investments in companies in Thuringia, with a fund volume under 
management totalling approx. 165 million euros.
About DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
(DEWB AG, Prime Standard, Securities No.: 804100 / ISIN: 
DE0008041005) is an investment company that specialises in young and 
established medium-sized companies. The focus of our investments is 
on strong growth companies from the areas of optics, optical-related 
technologies and sensor systems for which we provide support through 
shareholders´ equity, expertise in corporate development and our 
sector network. Our regional focus lies in the German speaking 
countries (D, A, CH). Since 1997 we have invested more than 300 
million Euros in 52 companies and realized more than 400 million 
Euros through 32 exits, eight of which were in the form of IPOs. The 
company is located in Jena, one of the most successful technology and
science regions in Germany, with a long tradition in the field of 
optical technologies and one of the most important European centres 
for Photonics.
About Zenteris Zenteris GmbH is a developer and manufacturer of 
biophotonic equipment used in the identification of biohazardous 
substances. As entire solutions, Zenteris products integrate the 
various links in the identification process chain and offer extremely
simple handling with a minimum analysis time. With its Approve-B 
system platform Zenteris currently has the most advanced technology 
at its disposal for the immunological or nucleic acid-based 
identification of various pathogens in a one-step analysis. Zenteris 
GmbH is a spin-off from JENOPTIK Laser, Optik, Systeme GmbH which in 
future will hold 24.9 percent of the shares.
end of announcement                               euro adhoc 08.08.2007 10:47:00

Further inquiry note:

Dr. Guido Bohnenkamp
bm-t gmbh
Phone: +49 (0) 361 7447 610
Fax: +49 (0) 361 7447 635
E-Mail: info@bm-t.com
www.bm-t.com

Mirko Wäckerle
DEWB AG
Phone: +49 (0) 3641 573 3600
Fax: +49 (0) 3641 573 3610
E-Mail: ir@dewb-vc.com
www.dewb-vc.com

Dr. Claudia Gluch
Zenteris GmbH
Phone: +49 (0) 3641 653606
Fax: +49 (0) 3641 652165
E-Mail: info@zenteris.de
www.zenteris.de

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade

Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
  • 03.05.2007 – 10:21

    DEWB´s portfolio company NOXXON closes 37 mill. EUR financing round

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. investments/NOXXON Financing Round Jena/Berlin (euro adhoc) - Jena/Berlin, May 3, 2007 - DEWB´s portfolio company NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the successful ...

  • 17.04.2007 – 16:03

    euro adhoc: Deutsche Effecten- und Wechsel-Beteiligungsges. AG / Director's Dealings

    Notification concerning transactions by persons discharging managerial responsibilities pursuant to section 15a of the WpHG, transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. 17.04.2007 ausserboerslich (euro adhoc) - Details of the person subject to the ...

  • 17.04.2007 – 15:32

    euro adhoc: Deutsche Effecten- und Wechsel-Beteiligungsges. AG / Director's Dealings

    Notification concerning transactions by persons discharging managerial responsibilities pursuant to section 15a of the WpHG, transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. 17.04.2007 XETRA (euro adhoc) - Details of the person subject to the disclosure requirement: Name: ...